Table 1 Clinical characteristics of patients with CHB at baseline and on-treatment emergent low-level viremia
Characteristics | All patients (n = 117) | ConTa (n = 71) | SwiTb (n = 15) | P value (a vs. b) | ComTc (n = 31) | P value (a vs. c) | VR† (n = 74) | NVR† (n = 43) | P value |
|---|---|---|---|---|---|---|---|---|---|
Age, years | 13.14 ± 2.70 | 12.92 ± 2.74 | 13.61 ± 2.54 | 0.37 | 13.39 ± 2.71 | 0.42 | 12.98 ± 2.84 | 13.40 ± 2.44 | 0.38 |
Sex, male/female | 77/40 | 45/26 | 10/5 | 0.83 | 22/9 | 0.44 | 49/25 | 28/15 | 0.90 |
BMI, kg/m 2 | 18.53 ± 3.71 | 18.25 ± 3.73 | 19.76 ± 3.18 | 0.15 | 18.58 ± 3.88 | 0.69 | 19.12 ± 3.83 | 17.53 ± 3.29 | 0.025 |
HBV genotype, B/C/other‡ | 41/74/2 | 25/45/1 | 5/10/0 | 0.93 | 11/19/1 | 0.91 | 34/38/2 | 7/36/0 | 0.002 |
ALT, U/L | 100(82–121) | 98(84–120) | 92(67–108) | 0.57 | 109(83–125) | 0.28 | 102(82–122) | 95(84–121) | 0.74 |
HBeAg, positive/negative | 98/19 | 60/11 | 12/3 | 0.67 | 26/5 | 0.93 | 58/16 | 40/3 | 0.038 |
Baseline | |||||||||
qHBsAg, log10 IU/mL | 4.27(4.09–4.51) | 4.25(4.07–4.43) | 4.27(4.02–4.46) | 0.65 | 4.39(4.10–4.66) | 0.19 | 4.26(4.07–4.43) | 4.27(4.02–4.46) | 0.62 |
HBV DNA, log10 IU/mL | 7.48(6.89–7.76) | 7.39(6.88–7.66) | 7.52(6.75–7.60) | 0.63 | 7.69(6.93–7.94) | 0.12 | 7.39(6.88–7.66) | 7.52(6.75–7.60) | 0.007 |
HBV RNA, log10 copies/mL | 6.55(6.20–6.86) | 6.56(6.21–6.89) | 6.54(6.20–6.82) | 0.65 | 6.55(6.14–6.87) | 0.84 | 6.54(6.21–6.89) | 6.56(6.20–6.82) | 0.06 |
Week 48 | |||||||||
qHBsAg, log10 IU/mL | 3.90(3.51–4.12) | 3.89(3.52–4.04) | 3.86(3.73–4.02) | 0.71 | 3.99(3.45–4.28) | 0.43 | 3.88(3.46–4.08) | 3.90(3.67–4.19) | 0.22 |
HBV DNA, log10 IU/mL | 2.61(2.13–2.95) | 2.51(2.02–2.87) | 2.78(2.48–2.96) | 0.08 | 2.77(2.23-3.00) | 0.038 | 2.23(2.01–2.73) | 2.89(2.62–3.09) | < 0.001 |
HBV RNA, log10 copies/mL | 3.77(3.04–4.03) | 3.54(2.95–3.97) | 3.95(3.75–4.16) | 0.008 | 3.79(3.34–4.30) | 0.08 | 3.48(2.98–3.90) | 4.06(3.54–4.33) | < 0.001 |